Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.56 |
| ▸ | RXRA | P19793 | 7/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | EDNRA | P25101 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16188440 | 1.00 | PPARG (0.56) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL13653162 | 0.90 | PPARG (0.56) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL13653157 | 0.89 | PPARG (0.55) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL13653161 | 0.89 | PPARG (0.55) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL11882613 | 0.87 | PPARG (0.56) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL11882623 | 0.87 | PPARG (0.56) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL13220675 | 0.87 | PPARG (0.53) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL10280515 | 0.87 | PPARG (0.56) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL15684626 | 0.87 | PPARG (0.61) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL13653163 | 0.87 | PPARG (0.61) | PPARGRXRACYP1A2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703975-B2 | Aryl (ethanoic) propanoic acid ascorbyl ester, preparation method thereof and medicament containing the same | WUXI HONGRUI BIO-PHARMA-TECH CO., LTD. (CN) | 2014-04-22 | — | — | US | disclosed |
| US-8703975-B2 | Aryl (ethanoic) propanoic acid ascorbyl ester, preparation method thereof and medicament containing the same | WUXI HONGRUI BIO-PHARMA-TECH CO., LTD. (CN) | 2014-04-22 | — | — | US | disclosed |
| US-20120115897-A1 | Aryl (Ethanoic) Propanoic Acid Ascorbyl Ester, Preparation Method Thereof And Medicament Containing The Same | WUXI HONGRUI BIO-PHARMA-TECH CO., LTD . (CN) | 2012-05-10 | — | — | US | disclosed |
| US-20120115897-A1 | Aryl (Ethanoic) Propanoic Acid Ascorbyl Ester, Preparation Method Thereof And Medicament Containing The Same | WUXI HONGRUI BIO-PHARMA-TECH CO., LTD . (CN) | 2012-05-10 | — | — | US | disclosed |
| EP-2431361-A1 | ASCORBIC ACID ARYL ACETATE/PROPIONATE ESTER, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | Wuxi Hongrui Biomedical Technology Co., Ltd. (CN) | 2012-03-21 | — | — | EP | disclosed |
| US-20100137599-A1 | PROCESS FOR PREPARING 1,4-BUTANDIOL MONITRATE | NICOX S.A. (FR) | 2010-06-03 | — | — | US | disclosed |
| US-7723382-B2 | Process for preparing nitrooxyalkyl substituted esters of carboxylic acids, intermediates useful in said process and preparation thereof | NICOX S.A. (FR) | 2010-05-25 | — | — | US | disclosed |
| US-7629368-B2 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2009-12-08 | — | — | US | disclosed |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | CANNIZZARO CARINA | 2009-10-01 | — | — | US | disclosed |
| US-20090048219-A1 | ORGANIC NITRIC OXIDE DONOR SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2009000723-A1 | PROCESS FOR PREPARING 1,4-BUTANDIOL MONONITRATE | NICOX S.A. (FR) | 2008-12-31 | — | — | WO | disclosed |
| US-7465803-B2 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-7432261-B2 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080194651-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. | 2008-08-14 | — | — | US | disclosed |
| EP-1594472-B1 | DELIVERY OF A NSAID FROM EMBOLIC AGENTS | BIOCOMPATIBLES UK LTD (GB) | 2007-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137599-A1 | PROCESS FOR PREPARING 1,4-BUTANDIOL MONITRATE | CYP11B1, CYP11B2, HSD17B7 | PPARG 1875/4885RXRA 3851/4885CYP1A2 55/4885 |
| US-20090048219-A1 | ORGANIC NITRIC OXIDE DONOR SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS3, NOS1, NOS2 | PPARG 2562/4885RXRA 4514/4885CYP1A2 528/4885 |
| US-20080194651-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NR3C1, NR2E1, CYP2E1 | PPARG 537/4885RXRA 303/4885CYP1A2 27/4885 |
| US-20120115897-A1 | Aryl (Ethanoic) Propanoic Acid Ascorbyl Ester, Preparation Method Thereof And Medicament Containing The Same | HTRA2, CYP27A1, ALOX15 | PPARG 210/4885RXRA 448/4885CYP1A2 246/4885 |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | PHOSPHO1, TNF, PTGES | PPARG 231/4885RXRA 1906/4885CYP1A2 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.